R&D products

LNC Therapeutics is working on the first gut modulator project initiated by a Medical Nutrition Product : STABLOR

Yesterday

Stablor

Medical Nutrition Product

Today

Temys Project

Gut microbiota directed drugs

 logo66

We are convinced that novel therapies will revolutionize obesity management.

As a result of comprehensive action on gut modulation, they will ensure safety, efficacy
and long-term results.

+ learn more

OBESITY & MICROBIOME

In a single decades, scientific research revealed the microbiome amazing abilities on health. Gut microbiota has emerged as a driving force in the development of obesity and its metabolic disorders.

 

While current strategies to prevent overweight and obesity have demonstrated their limitations, new therapies based on the microbiota now constitute the future for the fight against obesity.

On the strength of promising results obtained on Stablor,

LNC Therapeutics is heading a development projet called Temys project

WHAT TEMYS Project IS ABOUT ?

Through Temys Project, LNC Therapeutics is developing innovative gut microbiota directed drugs 

INTESTINAL ECOSYSTEM MODULATION


Temys Project
aims to restore intestinal ecosystem by microbiome modulation, inflammation decrease and gut permeability improvement (action on mucus, epithelium and tight junctions)

PATIENT PROFILE

  • BMI > 25
  • Waist circumference
    • > 94cm for men
    • > 80cm for women
  • 2 cardiometabolic risk factors

Discover Stablor, the first microbiome modulator against obesity

STABLOR
Medical Nutrition Product
Publications

In order to be on the cutting edge of scientific research and innovation, we select and analyse key scientific publications and materials

Discover our selection

Find out more
LNC Therapeutics appoints new...
After €6.5 million of fundraising and the arrival of a new Chief Scientific Officer in 2017, LNC...
Le microbiote intestinal, un...
Ces milliards de bactéries qui peuplent notre tube digestif jouent un rôle très important dans de...
LNC lève 6,5M€ pour cibler...
Si l'intestin a un charme discret, son potentiel clinique ne l'est pas. Pour développer...
Les levées de fonds de la...
Obésité : LNC Therapeutics, qui met au point un traitement contre l'obésité et les maladies...